For decades, randomised clinical trials have been the gold standard for demonstrating a potential new medicine is safe & effective. Nowadays, however, payers, policymakers and suffering patients are demanding more.
As the research and healthcare landscape shifts towards increasing personalisation of treatment, rising emergence of rare diseases and earlier access, it is grappling simultaneously with high costs and lengthy timelines when delivering medicine to patients. Real world evidence has the potential to help facilitate access and address some of this burden, whilst providing a better understanding of medicines ‘real world’ use.
Real-World Data (RWD) is data relating to patient health status and the delivery of healthcare collected regularly from a variety of sources. These sources provide reliable evaluations on three pillars of RWE Studies.
RWE analytics delivers valuable information, from the frontline of healthcare systems. This data leads the conversation with payers, healthcare providers, and regulators to make more holistic and informed healthcare decisions.
Improved data collection enables safer studies when scaling study populations, whilst upholding gold standard patient care and integration.